Preparation method of γ-arylbutenolide compounds and their application in the preparation of cardiovascular protective drugs
By isolating and purifying γ-arylbutenelactone compounds from the fermentation culture of the co-epidemic fungus of the marine herbal soft coral Aspergillus sp.EGF7-0-1, the problems of insufficient application of such compounds in the prior art were solved, and the pharmacoefficient material basis for cardiovascular disease was achieved.
Patent Information
- Application Number
- CN202310726346.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-06-16
- Publication Date
- 2025-07-18
- Estimated Expiration
- 2043-06-16
AI Technical Summary
In the prior art, there are few studies on the isolation of natural products of γ-arylbutene lactone compounds, structural diversity and biological activity, and the application in cardiovascular protection drugs has not been fully explored.
The novel structured γ-arylbutene lactone compounds were isolated from the fermentation culture of the co-epidemic fungus of marine herbal soft coral Aspergillus sp.EGF7-0-1, and a variety of compounds were purified by a series of chromatography and chromatography techniques, and the structure was further identified by NMR, MS, UV, CD/ECD, XRD and other technologies.
It was discovered for the first time that these compounds have protective effects on cardiovascular, providing a pharmacokinetic material basis for the study of cardiovascular diseases, and realizing the application of γ-arylbutene lactone compounds in cardiovascular protection drugs.
Smart Images

Figure CN116947831B_ABST
Abstract
Description
Technical Field:
[0001] The present invention relates to the field of pharmaceutical biotechnology, and particularly relates to a preparation method of γ-arylbutenolide compounds and their application in the preparation of cardiovascular protective drugs. Background Art:
[0002] γ-arylbutenolide compounds refer to a class of natural products with a four-carbon heterocyclic lactone and substituted by 3-phenyl and 4-benzyl substituents. In terms of habitat / source, γ-butenolide mainly comes from marine microorganisms, endophytic fungi in plant and animal samples, and environmental fungi isolated from soil, etc. According to statistics, currently 176 γ-butenolide compounds have been reported, among which 106 compounds come from marine microorganisms, accounting for 54% of the total. 57 compounds come from plant endophytic fungi, accounting for 29%. The bioactivity analysis of 176 compounds shows that 68.2% (120) of the compounds exhibit a wide range of pharmacological activities, including antioxidant (32), antiviral (30), α-glucosidase inhibition (28), antibacterial (25), anti-inflammatory (13), antitumor (12), cytotoxicity (5), antifouling (5), etc. The remaining active compounds exhibit other activities (9 compounds, accounting for 6%), such as enhancing learning and memory activity and protective activity (3 compounds, accounting for 2.4%), etc.
[0003] With the continuous increase of new γ-butenolide compounds, reviews of such structures have also been reported. For example, Joe and his colleagues have reviewed the butenolides in marine microorganisms, but they only focused on three types of butenolides (rubrolides, cadiolides, and prunolides) in marine tunicates. Chatterjee et al. reviewed the synthetic strategies of γ-butenolide compounds from 2010 to 2022, mainly focusing on the synthesis of γ-butenolide, but there is less research on aspects such as the isolation of its natural products, structural diversity, and biological activity. Natural products have more significant structural diversity and complexity compared to synthetic products, and at the same time have a higher screening rate in terms of biological activity. Summary of the Invention:
[0004] The purpose of the present invention is to provide a γ-arylbutenolide compound, its preparation method, and its application in the preparation of cardiovascular protective drugs.
[0005] The present invention is achieved through the following technical solutions:
[0006] γ-arylbutenolide compounds, the structural formula of which is as follows:
[0007]
[0008] The preparation method of the γ-arylbutenolide compound is characterized in that it is isolated from the fermentation culture of the symbiotic fungus Aspergillus sp. EGF7-0-1 of the marine herbal soft coral (Sinulariasp.).
[0009] Specifically, it includes the following steps:
[0010] 1) Prepare a single culture medium or a co-culture medium of the symbiotic fungus Aspergillus sp. EGF7-0-1 of the marine herbal soft coral (Sinularia sp.);
[0011] 2) Extract the single culture medium or co-culture medium combined with the mycelium with ethyl acetate respectively, and then concentrate the extract to obtain the ethyl acetate extract of rice single culture or the ethyl acetate extract of rice co-culture;
[0012] 3) Separate the ethyl acetate extract of rice single culture by silica gel column chromatography, and elute with petroleum ether / ethyl acetate with V PE :V EtOAc = 100:0 → 0:100 to obtain 11 crude fractions, Fr.1 - Fr.11. Separate the 5th crude fraction Fr.5 by silica gel column chromatography, and elute with CH2Cl2 / MeOH with V CH2Cl2 :V MeOH = 80:1 → 0:100 to obtain 6 fractions, Fr.5-1 - Fr.5-6. Fr.5-1 is eluted through a silica gel column chromatography with V CH2Cl2 :V MeOH = 80:1 → 0:100 of CH2Cl2 / MeOH to obtain 3 fractions, namely Fr.5-1-1 - Fr.5-1-3; Fr.5-1-2 is separated by Sephadex LH-20 gel column chromatography and eluted with methanol to obtain 5 sub-fractions (Fr.5-1-2-1 - Fr.5-1-2-5); Using V MeOH :V H2O = 65:35 as the mobile phase, purify the 2nd sub-fraction Fr.5-1-2-2 by SP-HPLC (flow rate: 3 ml / min) to obtain compound F13 with a retention time of 16.5 min, compound F8 with a retention time of 23.0 min, compound F12 with a retention time of 36.5 min, and compound F9 with a retention time of 45.4 min; The 4th sub-fraction Fr.5-1-2-4 is subjected to SP-HPLC, with V MeOH :V H2O= 55:45 was used for mobile phase purification to obtain compound F2 with a retention time of 16.5 min and compound F1 with a retention time of 40.2 min; the 5th fraction, Fr.5-5, was separated by Sephadex LH-20 gel column chromatography and eluted with methanol to obtain four subgroups, Fr.5-5-1 to Fr.5-1-4; with V MeOH :V H2O = 60:40 as the mobile phase, the 1st subgroup, Fr.5-5-1, was purified by SP-HPLC to obtain compound F10 with a retention time of 23.2 min and compound F11 with a retention time of 42.0 min;
[0013] The ethyl acetate extract of the co-culture with rice was eluted with a petroleum ether-ethyl acetate system on a silica gel column (V PE :V EtOAc = 100:0 → 0:100), and 11 crude fractions, Fr.1 to Fr.11, were obtained by combining according to the thin-layer TLC situation; Fr.9 was eluted with CH2Cl2-MeOH (80:1 to 0:100) on a silica gel column to obtain 4 fractions, Fr.5-1 to Fr.5-4); Fr.5-1-2 was separated by Sephadex LH-20 gel column chromatography and eluted with methanol to obtain 5 sub-components, Fr.5-1-2-1 to Fr.5-1-2-6; with V MeOH :V H2O = 70:30 as the mobile phase, Fr.5-1-2-3 was purified by SP-HPLC to obtain compound F3 with a retention time of 16.5 min and compound F4 with a retention time of 23.0 min; Fr.5-1-2-4 was purified by SP-HPLC with V MeOH :V H2O = 65:35 as the mobile phase to obtain compound F7 with a retention time of 9.0 min, compound F5 with a retention time of 40.2 min, and compound F6 with a retention time of 23.0 min.
[0014] Step 1) Preparation of the single culture medium or co-culture medium of the marine herbal soft coral (Sinularia sp.) co-associated fungus Aspergillus sp. EGF7-0-1 specifically includes the following steps:
[0015] a. Inoculate the marine herbal soft coral (Sinularia sp.) co-associated fungus Aspergillus sp. EGF7-0-1 into a culture flask containing PDA medium and culture it on a shaker at 28 °C to obtain an activated seed culture solution;
[0016] b. Inoculate the activated seed culture solution into a culture flask containing rice medium for single culture, or co-culture it with Aspergillus sp. EGF15-0-3 strain with the preservation number of GDMCC No. 60476, and statically culture at 28 °C for 30 days.
[0017] The formula of the rice medium is as follows: 100 g of rice, 115 mL of water, salinity 3.3%, and natural pH.
[0018] The formula of PDA medium: 200 g of potatoes, 20 g of glucose, 15 - 20 g of agar, 1000 mL of water, salinity 3.5%, and natural pH.
[0019] The inventors first isolated the above novel γ-arylidenebutenolide compounds from the fermentation culture of the co - epiphytic fungus Aspergillus sp. EGF7-0-1 of marine herbal soft coral (Sinularia sp.), and first discovered that the above compounds have a protective effect on the cardiovascular system, providing a pharmacodynamic material basis for the subsequent research on cardiovascular diseases.
[0020] Therefore, the present invention also protects the application of the above γ-arylidenebutenolide compounds in the preparation of cardiovascular protective drugs.
[0021] The beneficial effects of the present invention are as follows: The inventors first isolated the above novel γ-arylidenebutenolide compounds from the fermentation culture of the co - epiphytic fungus Aspergillus sp. EGF7-0-1 of marine herbal soft coral (Sinularia sp.), and first discovered that the above compounds have a protective effect on the cardiovascular system, providing a pharmacodynamic material basis for the subsequent research on cardiovascular diseases.
[0022] The co - epiphytic fungus Aspergillus sp. EGF7-0-1 of the marine herbal soft coral (Sinularia sp.) of the present invention has been disclosed in Fan Hao, He Jiahong, Wei Xia, Chen Leyi, Chen Xinqi, Zhang Cuixian, Study on phenolic acid chemical constituents in co - epiphytic fungus Aspergillus sp. EGF7-0-1 of marine herbal soft coral (II) (i.e., Aspergillus sp. EGF7-0-1 in this literature). This strain is also held by the applicant, and it is guaranteed to be provided to the public within 20 years from the application date.
[0023] The Aspergillus sp. EGF15-0-3 strain with the preservation number of GDMCC No. 60476 of the present invention was isolated from soft coral in the Sanya sea area of the South China Sea, and its species was identified as a fungus of the genus Aspergillus. It has been disclosed in CN109439705B, a method for microbial preparation of gorgonic acid. Description of the Drawings:
[0024] Figure 1 is the HRESIMS mass spectrum of compound F1;
[0025] Figure 2 is the IR spectrum of compound F1;
[0026] Figure 3 is of compound F1 1 1H NMR spectrum (400 MHz, CD3OD);
[0027] Figure 4 is of compound F1 13 13C NMR spectrum (100 MHz, CD3OD);
[0028] Figure 5 is the DEPT 135 (100 MHz, CD3OD) spectrum of compound F1;
[0029] Figure 6 is of compound F1 1 1H- 1 1H COSY spectrum;
[0030] Figure 7 is the HSQC spectrum of compound F1;
[0031] Figure 8 is the HMBC spectrum of compound F1;
[0032] Figure 9 is the NOESY spectrum of compound F1;
[0033] Figure 10 is of compounds F1 and F2 1 1H- 1 1H-COSY, key HMBC and NOE correlation schematic diagrams;
[0034] Figure 11 is the measured and calculated ECD spectra (left) and single crystal X-ray diffraction structure diagram (right) of compound F1;
[0035] Figure 12 is the HRESIMS mass spectrum of compound F2;
[0036] Figure 13 is the IR spectrum of compound F2;
[0037] Figure 14 is of compound F2 1 1H NMR spectrum (400 MHz, CD3OD);
[0038] Figure 15 is of compound F213 13C NMR spectrum (100 MHz, CD3OD);
[0039] Figure 16 is the DEPT 135 (100 MHz, CD3OD) spectrum of compound F2;
[0040] Figure 17 is of compound F2 1 1H- 1 1H COSY spectrum;
[0041] Figure 18 is the HSQC spectrum of compound F2;
[0042] Figure 19 is the HMBC spectrum of compound F2;
[0043] Figure 20 is of compounds F3 and F4 1 1H- 1 1H-COSY, key HMBC correlation schematic diagram;
[0044] Figure 21 HRESIMS spectrum of compound F3;
[0045] Figure 22 is the IR spectrum of compound F3;
[0046] Figure 23 is of compound F3 1 1H NMR spectrum (400 MHz, CD3OD);
[0047] Figure 24 is of compound F3 13 13C NMR spectrum (100 MHz, CD3OD);
[0048] Figure 25 is the DEPT 135 (100 MHz, CD3OD) spectrum of compound F3;
[0049] Figure 26 is of compound F3 1 1H- 1 1H COSY spectrum;
[0050] Figure 27 is the HSQC spectrum of compound F3;
[0051] Figure 28 is the HMBC spectrum of compound F3;
[0052] Figure 29 is the single crystal X-ray diffraction structure diagram of compound F3;
[0053] Figure 30 is the single crystal X-ray diffraction structure diagram of compound F4;
[0054] Figure 31 HRESIMS spectrum of compound F4;
[0055] Figure 32 is the IR spectrum of compound F4;
[0056] Figure 33 is of compound F4 1 1H NMR spectrum (400 MHz, CD3OD);
[0057] Figure 34 is of compound F4 13 13C NMR spectrum (100 MHz, CD3OD);
[0058] Figure 35 is the DEPT 135 (100 MHz, CD3OD) spectrum of compound F4;
[0059] Figure 36 is of compound F4 1 1H- 1 1H COSY spectrum;
[0060] Figure 37 is the HSQC spectrum of compound F4;
[0061] Figure 38 is the HMBC spectrum of compound F4;
[0062] Figure 39 is of compounds F5 and F6 1 1H- 1 1H-COSY, key HMBC correlation schematic diagram;
[0063] Figure 40 is the measured and calculated ECD spectra of compounds F5 - F6;
[0064] Figure 41 HRESIMS spectrum of compound F5;
[0065] Figure 42 is the IR spectrum of compound F5;
[0066] Figure 43 is of compound F5 1 1H NMR spectrum (400 MHz, CD3OD);
[0067] Figure 44 is of compound F5 13 13C NMR spectrum (100 MHz, CD3OD);
[0068] Figure 45 It is the DEPT 135 (100 MHz, CD3OD) spectrum of compound F5;
[0069] Figure 46 It is of compound F5 1 H- 1 H COSY spectrum;
[0070] Figure 47 It is the HSQC spectrum of compound F5;
[0071] Figure 48 It is the HMBC spectrum of compound F5;
[0072] Figure 49 The HRESIMS spectrum of compound F6;
[0073] Figure 50 It is the IR spectrum of compound F6;
[0074] Figure 51 It is of compound F6 1 1H NMR spectrum (400 MHz, CD3OD);
[0075] Figure 52 It is of compound F6 13 13C NMR spectrum (100 MHz, CD3OD);
[0076] Figure 53 It is the DEPT 135 (100 MHz, CD3OD) spectrum of compound F6;
[0077] Figure 54 It is of compound F6 1 H- 1 H COSY spectrum;
[0078] Figure 55 It is the HSQC spectrum of compound F6;
[0079] Figure 56 It is the HMBC spectrum of compound F6;
[0080] Figure 57 It is of compounds F7, F8 and F9 1 H- 1 H-COSY, key HMBC correlation schematic diagrams;
[0081] Figure 58 It is the measured and calculated ECD spectra of compounds F7 - F9;
[0082] Figure 59 The HRESIMS spectrum of compound F7;
[0083] Figure 60 It is the IR spectrum of compound F7;
[0084] Figure 61 It is of compound F7 1 1H NMR spectrum (400 MHz, CD3OD);
[0085] Figure 62 It is of compound F7 13 13C NMR spectrum (100 MHz, CD3OD);
[0086] Figure 63 It is the DEPT 135 (100 MHz, CD3OD) spectrum of compound F7;
[0087] Figure 64 It is of compound F7 1 H- 1 H COSY spectrum;
[0088] Figure 65 It is the HSQC spectrum of compound F7;
[0089] Figure 66 It is the HMBC spectrum of compound F7;
[0090] Figure 67 The HRESIMS spectrum of compound F8;
[0091] Figure 68 It is the IR spectrum of compound F8;
[0092] Figure 69 It is of compound F8 1 1H NMR spectrum (400 MHz, CD3OD);
[0093] Figure 70 It is of compound F8 13 13C NMR spectrum (100 MHz, CD3OD);
[0094] Figure 71 It is the DEPT 135 (100 MHz, CD3OD) spectrum of compound F8;
[0095] Figure 72 It is of compound F8 1 H- 1 H COSY spectrum;
[0096] Figure 73 It is the HSQC spectrum of compound F8;
[0097] Figure 74 It is the HMBC spectrum of compound F8;
[0098] Figure 75 HRESIMS spectrum of compound F9;
[0099] Figure 76 It is the IR spectrum of compound F9;
[0100] Figure 77 It is that of compound F9 1 1H NMR spectrum (400 MHz, CD3OD);
[0101] Figure 78 It is that of compound F9 13 13C NMR spectrum (100 MHz, CD3OD);
[0102] Figure 79 It is the DEPT 135 (100 MHz, CD3OD) spectrum of compound F9;
[0103] Figure 80 It is that of compound F9 1 H- 1 H COSY spectrum. Detailed implementation mode:
[0104] The following is a further description of the present invention, rather than a limitation thereof.
[0105] Example 1: Preparation of γ-arylbutenolide compounds
[0106] I. Microbial fermentation
[0107] Composition of the culture medium: Rice culture medium: 100 g of rice, 115 mL of water, salinity 3.3%, pH natural.
[0108] PDA culture medium: 200 g of potato, 20 g of glucose, 20 g of agar, 1000 mL of water, salinity 3.5%, pH natural.
[0109] Activation of the strain: Use an inoculation loop to pick the strain Aspergillus sp. EGF7-0-1, an endophytic fungus symbiotic with the marine herbal soft coral, from the strain tube into a culture flask containing PDA culture medium (400 mL / 1000 mL), and place it in a constant temperature shaker at 28 °C (165 r / min) for 2 days to obtain a seed solution.
[0110] Inoculation: Pipette 10 mL of the activated seed culture solution into a 1 L culture flask containing 400 mL of rice culture medium for single culture to obtain 200 L of single culture medium, and pipette 10 mL of the activated seed culture solution and the EGF15-0-3 strain into a 1 L culture flask containing 400 mL of rice culture medium for co-culture to obtain 400 L. Place the above culture medium in a room at 28 °C and let it stand for 30 days.
[0111] II. Separation of γ - arylbutenolide compounds:
[0112] Extraction: After the cultivation of Aspergillus sp. EGF7 - 0 - 1 in rice monoculture and co - culture strains was completed, 250 mL of EtOAc was added to each culture flask, and the mixture was placed on a shaker and shaken at 165 r / min for 3 times (8 h each time). After filtration, the EtOAc extracts were combined, and after concentration under reduced pressure, the ethyl acetate extract from rice monoculture (500.0 g) and the ethyl acetate extract from rice co - culture (1250.0 g) were obtained respectively.
[0113] Separation: The ethyl acetate extract from rice monoculture (500.0 g) obtained from 200 L of rice medium was subjected to silica gel column chromatography (φ = 12.5 cm, l = 110 cm, silica gel for column packing 2.3 kg (height 57 cm), column volume 3.85 L) and eluted with a petroleum ether - ethyl acetate system (V PE :V EtOAc = 100:0 → 0:100, 1 L / bottle). According to the thin - layer TLC situation, 11 crude fractions Fr.1 - Fr.11 were combined. Fr.5 (200.0 g) was eluted with CH2Cl2 - MeOH (80:1 - 0:100) on silica gel column chromatography to obtain 6 fractions (Fr.5 - 1 - Fr.5 - 6). Fr.5 - 1 was eluted with V CH2Cl2 :V MeOH = 80:1 - 0:100 of CH2Cl2 / MeOH on silica gel column chromatography to obtain 3 fractions, namely Fr.5 - 1 - 1 - Fr.5 - 1 - 3. Fr.5 - 1 - 2 (3.0 g) was separated by Sephadex LH - 20 gel column chromatography and eluted with methanol to obtain 5 sub - fractions (Fr.5 - 1 - 2 - 1 - Fr.5 - 1 - 2 - 5). Using V MeOH :V H2O = 65:35 as the mobile phase, Fr.5 - 1 - 2 - 2 (1.2 g) was purified by SP - HPLC (flow rate: 3 ml / min) to obtain 12.6 mg of compound F13 with a retention time of 16.5 min, F8 (t R = 23.0 min, 15.5 mg), 10.2 mg of compound F12 with a retention time of 36.5 min, and 12.2 mg of compound F9 with a retention time of 45.4 min. Fr.5 - 1 - 2 - 4 (2.0 g) was subjected to SP - HPLC (flow rate: 3 mL / min), using V MeOH :V H2O= 55:45 was used for mobile phase purification to obtain 2.5 mg of compound F2 with a retention time of 16.5 min and 4.0 mg of compound F1 with a retention time of 40.2 min. Fr.5-5 (1.5 g) was separated by Sephadex LH-20 gel column chromatography and eluted with methanol to obtain four subgroups (Fr.5-5-1 to Fr.5-1-4). With V MeOH :V H2O = 60:40 as the mobile phase, Fr.5-5-1 (0.4 g) was purified by SP-HPLC (flow rate: 3 mL / min) to obtain 8.0 mg of compound F10 with a retention time of 23.2 min and 25.8 mg of compound F11 with a retention time of 42.0 min.
[0114] The ethyl acetate extract from the rice co-culture (1250.0 g) was eluted with a petroleum ether-ethyl acetate system on a silica gel column (V PE :V EtOAc = 100:0 → 0:100, 1 L / bottle), and 11 crude fractions Fr.1 to Fr.11 were obtained by combining according to the thin layer TLC situation. Fr.9 (10.0 g) was eluted with CH2Cl2-MeOH (80:1 to 0:100) on a silica gel column to obtain 4 fractions (Fr.5-1 to Fr.5-4). Fr.5-1-2 (5.0 g) was separated by Sephadex LH-20 gel column chromatography and eluted with methanol to obtain 5 subgroups (Fr.5-1-2-1 to Fr.5-1-2-6). With V MeOH :V H2O = 70:30 as the mobile phase, Fr.5-1-2-3 (0.3 g) was purified by SP-HPLC (flow rate: 3 mL / min) to obtain 15.6 mg of compound F3 with a retention time of 16.5 min and 12.3 mg of compound F4 with a retention time of 23.0 min. Fr.5-1-2-4 (2.0 g) was purified by SP-HPLC (flow rate: 2 mL / min) with MeOH :V H2O = 65:35 as the mobile phase to obtain 3.0 mg of compound F7 with a retention time of 9.0 min, 30.5 mg of compound F5 with a retention time of 40.2 min, and 15.5 mg of compound F6 with a retention time of 23.0 min.
[0115] The structural formula is as follows:
[0116]
[0117] III. Structural identification of γ-arylidene lactone compounds:
[0118] The structures of the isolated compounds were determined by NMR, MS, UV, CD / ECD, XRD, ORD and other techniques.
[0119] Aspergteroid G (Compound F1) is a colorless crystal (MeOH), and its structure was determined as follows:
[0120] As Figure 1-9 shown, Figure 1 is the HRESIMS mass spectrum of Compound F1; Figure 2 is the IR spectrum of Compound F1; Figure 3 is that of Compound F1 1 1H NMR spectrum; Figure 4 is that of Compound F1 13 13C NMR spectrum; Figure 5 is the DEPT 135 (100 MHz, CD3OD) spectrum of Compound F1; Figure 6 is that of Compound F1 1 H- 1 H COSY spectrum; Figure 7 is the HSQC spectrum of Compound F1; Figure 8 is the HMBC spectrum of Compound F1; Figure 9 is the NOESY spectrum of Compound F1.
[0121] See Figure 1 HRESIMS gave the quasi-molecular ion peak m / z: 364.1542 [M-H] - (calcd: 364.1549), determining its molecular formula to be C 22 H 23 NO4, with an unsaturation degree of 12. [α] 25 D +64.6 (c 0.10, MeOH); UV (MeOH) λ max (logε): 229 (3.69), 278 (3.08); IR (neat)νmax : 3292, 1705, 1515, 1496 cm -1 ; 1 The 1H NMR spectrum showed the presence of a pair of substituted phenols (A2B2 system) δ H 7.58 (d, 8.8 Hz, 2H) and 6.87 (d, 8.8 Hz, 2H), and three aromatic ring proton signals δ H 6.83 (s, 1H), 6.58 (d, 8.2 Hz, 1H) and 6.85 (d, 8.2 Hz, 1H), suggesting the presence of an additional asymmetric trisubstituted benzene ring. 13 The 13C NMR spectrum showed 22 well-resolved resonance peaks, including two carbonyl carbons δ C181.3 (C), 181.7 (C), and two methyl δ C 53.2 (CH) and 53.6 (CH) are characteristic of the maleimide structure. Ten aromatic ring proton signals are attributed to the aromatic ring, and three methylene signals δ C 23.3 (CH2), 33.8 (CH2), and 35.6 (CH2), and one oxygen - linked quaternary carbon δ C 75.2 (C).
[0122] Further analysis of the two - dimensional spectra Figure 7 (HSQC, Table 1), in 1 H - 1 the H - Figure 6 COSY spectrum( H ) H - 3 (δ H 3.64, d, 5.7) / H - 4 (δ H 3.16, m); H - 2'(6') (δ H 6.76, d, 8.6) / H - 3'(5') (δ H 6.63, d, 8.6) H - 5” (δ H 6.58, d, 8.2) / H - 6” (δ H 6.85, d, 8.2) and H - 7” (δ H 2.66, m) / H - 8” (δ Figure 8 In the HMBC spectrum of H H - 3 (δ C 3.64, d, 5.7) / C - 2 (δ C 181.2, C), C - 5 (δ C 181.7, C), and C - 1' (δ H 129.7, C); H - 4 (δ C 3.16, m) / C - 2 (δ C 181.3, C), C - 5 (δ C 181.7, C), and C - 1” (δ a -6 (δ H 2.88, dd, 13.8, 8.5) and H b -6 (δ H 3.13, m) / C - 3 (δ C 53.2, CH), C - 4 (δ C 53.6, CH), C - 5 (δ C 181.7, C), C - 1” (δ C 129.7, C), C - 2” (δ C131.4, C), and C-6” (δ C 129.3, C); H-7” (δ H 2.66, m) / C-2” (δ C 131.4, C), C-3” (δ C 123.3, C), C-4” (δ C 154.1, C), and C-9” (δ C 75.2, C); H-8” (δ H 1.76, t, 6.8) / C-3” (δ C 123.3, C), C-9” (δ C 75.2, C), and C-10” (δ C 26.9, C); H-11” (δ H 1.28, s) / C-9” (δ C 75.2, C), and C-10” (δ C 26.9, C) to determine the planar structure of compound F1 (see Figure 5 ).
[0123] According to Figure 9 in the NOESY spectrum, the correlations of H-3 (δ H 3.64, d, 5.7) and H-6 (δ H H-6a: 2.88, dd, 13.8, 8.5; H-6b: 3.13, m) suggest that the H-3 and H-6a, H-6b protons are coplanar. The absolute configuration of compound F1 was determined by single-crystal X-ray diffraction experiment and quantum chemical ECD calculation. The Flack parameter was 0.02(11), and the absolute configuration of F1 was determined to be 3S, 4R. (Figure 11).
[0124] Table 1. 1 1H NMR and 13 13C NMR spectroscopic data (δ in ppm, J in Hz, solvent methanol) of compounds F1 - F2
[0125]
[0126] Aspergteroid H (compound F2) is a pale yellow oily gum (MeOH), UV (MeOH) λ max (log ε): 224(3.95), 276(2.76); IR (neat)νmax : 3321, 1705, 1514, 1240 cm -1 ; Figure 12 is the HRESIMS mass spectrum of compound F2;
[0127] Figure 13 is the IR spectrum of compound F2; Figure 14 is of compound F2 1 1H NMR spectrum (400 MHz, CD3OD); Figure 15 is of compound F2 13 13C NMR spectrum (100 MHz, CD3OD); Figure 16 is the DEPT 135 (100 MHz, CD3OD) spectrum of compound F2; Figure 17 is of compound F2 1 H- 1 H COSY spectrum; Figure 18 is the HSQC spectrum of compound F2; Figure 19 is the HMBC spectrum of compound F2.
[0128] The quasi-molecular ion peak m / z: 294.0768 [M-H] given by HRESIMS - (calculated value: 294.0766), determining its molecular formula to be C 17 H 13 NO4, with an unsaturation degree of 11.
[0129] Comparing the NMR data, it was found that the NMR data of compound F2 and compound F1 are extremely similar (see Table 1), suggesting that they may have the same structural fragment. Compared with compound F1, compound F2 has an additional para-substituted phenol (A2B2 system) at δ H 6.99 (d, 8.6 Hz, 2H) and 6.83 (d, 8.6 Hz, 2H), and signals of two olefinic carbon bonds at δ C 139.7 (C) and 138.2 (C), while three methylene signals at δ C 23.3 (CH2), 33.8 (CH2) and 35.6 (CH2) and a quaternary carbon with oxygen at δ C 75.2 (C) are missing in compound F2. In the 1H-1H-COSY spectrum( Figure 17 ), H-2'(6′) (δ H 6.76, d, 8.6) / H-3′(5′) (δ H 6.63, d, 8.6), H-2″(6″) (δ H 6.99, d, 8.6) / H-3″(4″) (δ H 6.83, d, 8.6), combined with the relevant signals in the HMBC spectrum( Figure 19 ), H-6 (δ H 2.80, s) / C-3 (δ C 139.7, C), C-4 (δ C138.2, C), C-5 (δ C 174.0, C), C-1” (δ C 129.8, C), and C-2”(6”) (δ C 130.3, C), thus determining the planar structure of compound F2 ( Figure 10 and Table 1).
[0130] Aspergteroid I (compound F3) is a colorless crystal (MeOH), [α] 25 D +38.7; UV (MeOH) λ max (logε): 224 (3.95), 280 (2.80); IR (neat)νmax : 3342, 1681, 1508, 1257 cm -1 , Figure 21 The HRESIMS spectrum of compound F3;
[0131] Figure 22 is the IR diagram of compound F3; Figure 23 is of compound F3 1 1H NMR spectrum (400 MHz, CD3OD); Figure 24 is of compound F3 13 13C NMR spectrum (100 MHz, CD3OD); Figure 25 is the DEPT 135 (100 MHz, CD3OD) spectrum of compound F3; Figure 26 is of compound F3 1 H- 1 H COSY spectrum; Figure 27 is the HSQC spectrum of compound F3; Figure 28 is the HMBC spectrum of compound F3; Figure 29 is the single crystal X-ray diffraction structure diagram of compound F3.
[0132] The HRESIMS spectrum ( Figure 21 ) gives a quasi-molecular ion peak m / z: 368.1500 [M-H] - (calculated value: 368.1498), determining its molecular formula to be C 21 H 23 NO5, with an unsaturation degree of 11. 1 The 1H NMR spectrum ( Figure 23 ) shows the presence of a set of para-substituted phenol (A2B2 system) δ H 8.09 (d, 8.9 Hz, 2H) and 6.78 (d, 8.9 Hz, 2H), and three aromatic ring proton hydrogen signals δ H6.85 (d, 2.0 Hz, 1H), 6.61 (d, 8.0 Hz, 1H) and 6.83 (dd, 8.0, 2.0 Hz, 1H), suggesting the presence of an additional asymmetric trisubstituted benzene ring. 13 The 13C NMR spectrum shows 21 well-resolved resonance peaks, including an isolated carbonyl carbon at δ C 196.7 (C) and an amide carbon signal at 176.4 (C). An isopentenyl group with a trisubstituted double bond has δ C 28.5 (CH2), 123.1 (CH), 133.0 (C), 25.9 (CH3), 17.7 (CH3) and two methylene signals at δ C 42.9 (CH2) and 29.2 (CH2).
[0133] Further analysis Figure 27 of the two-dimensional spectrum (HSQC) (see Table 2) shows, in the 1 H- 1 H-COSY spectrum ( Figure 26 ), H-2'(6') (δ H 8.09, d, 8.9) / H-3'(5') (δ H 6.78, d, 8.9); H-5” (δ H 6.61, d, 8.0) / H-6” (δ H 6.85, dd, 8.0, 2.0); H-7” (δ H 3.22, d, 7.3) / H-8” (δ H 5.25, t, 7.3). And Figure 28 in the HMBC spectrum, H-4a (δ H 3.19, d, 15.0), H-4b (δ H 3.29, d, 15.0) / C-2 (δ C 196.7, C), C-2 (δ C 84.6, C), C-1” (δ C 127.7, C); H-7” (δ H 3.22, d, 7.3) / C-2” (δ C 132.8, C), C-3” (δ C 127.6, C), C-4” (δ C 154.9, C) and C-9” (δ C 132.7, C); H-8” (δ H 5.25, t, 7.3) / C-3” (δ C 127.6, C), C-9” (δ C132.7, C) and C-10” (δ C 17.8, C); H-11” (δ H 1.67, s) / C-9” (δ C 132.7, C) and C-10” (δ C 17.8, C) to determine the planar structure of compound F3 (see Figure 20 ). The absolute configuration of compound F3 was determined by single-crystal X-ray diffraction experiment, and the Flack parameter was 0.04(8), determining the absolute configuration of F3 to be 3R. ( Figure 29 ).
[0134] Table 2. 1 1H NMR and 13 13C NMR data (δ in ppm, J in Hz, solvent methanol) of compounds F3 - F4
[0135]
[0136] Aspergteroid J (compound F4) colorless crystals (MeOH), [α] 25 D +33.8; UV (MeOH) λ max (log ε): 224(3.95), 280(2.80); IR (neat)νmax : 3363, 1716, 1558, 1261 cm -1 , Figure 30 is the single-crystal X-ray diffraction structure diagram of compound F4, Figure 31 the HRESIMS spectrum of compound F4; Figure 32 is the IR spectrum of compound F4; Figure 33 is of compound F4 1 1H NMR spectrum (400 MHz, CD3OD); Figure 34 is of compound F4 13 13C NMR spectrum (100 MHz, CD3OD); Figure 35 is the DEPT 135 (100 MHz, CD3OD) spectrum of compound F4; Figure 36 is of compound F4 1 H- 1 H COSY spectrum; Figure 37 is the HSQC spectrum of compound F4; Figure 38 is the HMBC spectrum of compound F4;
[0137] Figure 31 The quasi-molecular ion peak m / z: 368.1500 [M - H] given by HRESIMS in -(Calculated value: 368.1498), and its molecular formula was determined to be C 21 H 23 NO5, with an unsaturation degree of 11. The NMR data of compound F4 and compound F3 were extremely similar (see Table 1), suggesting that they might have the same structural fragment. In the 13 C NMR and DEPT spectra, compared with F3, F4 lacked an olefinic proton signal at δ H 5.25, t, 7.3 and two olefinic carbon signals at δ C 123.1 (CH), 133.0 (C). Compared with two methylenes and one oxygen-linked sp 3 carbon in F3, F4 contained three methylenes and two oxygen-linked sp 3 quaternary carbons. The data indicated that the dihydropyran ring was fused with a trisubstituted benzene ring, replacing the linear pentenyl group in F3, and combining with the Figure 36 1 H- 1 H COSY key correlation signals H-7” (δ H 2.71, t, 6.6) / H-8” (δ H 2.71, t, 6.6) and Figure 38 the relevant HMBC spectrum signals H-7” (δ H 2.71, t, 6.6) / C-2” (δ C 132.7, CH), C-3” (δ C 121.4, C), C-4” (δ C 154.0, C), C-8” (δ C 33.9, CH2) and C-9” (δ C 75.0, C); H-8” (δ H 2.71, t, 6.6) / C-3” (δ C 121.4, C), C-7” (δ C 23.4, CH2), C-9” (δ C 75.0, C) and C-10” (δ C 27.1, CH3) established a dihydropyran ring fused through the C3”-C4” bond of the benzene ring. The absolute configuration of compound F4 was determined by single-crystal X-ray diffraction experiment, and the Flack parameter was -0.2(2), determining the absolute configuration of F4 to be 3R. ( Figure 30 ).
[0138] Table 3. 1 1H NMR and 13 13C NMR data (δ in ppm, J in Hz, solvent methanol)
[0139]
[0140] Aspergteroid K (Compound F5) is a pale yellow oily gum, (MeOH), [α] 25 D +60.9; UV (MeOH) λ max (logε): 224 (3.95), 306 (4.43); IR (neat)νmax : 1238, 1004, 812 cm -1 .
[0141] Figure 41 is the HRESIMS spectrum of Compound F5; Figure 42 is the IR spectrum of Compound F5; Figure 43 is of Compound F5 1 1H NMR spectrum (400 MHz, CD3OD); Figure 44 is of Compound F5 13 13C NMR spectrum (100 MHz, CD3OD); Figure 45 is the DEPT 135 (100 MHz, CD3OD) spectrum of Compound F5; Figure 46 is of Compound F5 1 H- 1 H COSY spectrum; Figure 47 is the HSQC spectrum of Compound F5; Figure 48 is the HMBC spectrum of Compound F5; Figure 39 is of Compounds F5 and F6 1 H- 1 H-COSY, key HMBC correlation schematic diagram; Figure 40 is the measured and calculated ECD spectra of Compounds F5 - F6.
[0142] Figure 41 The quasi-molecular ion peak m / z: 408.1449 [M - H] given by HRESIMS in - (calculated value: 408.1447), determining its molecular formula to be C 23 H 23 NO6, with an unsaturation degree of 13. 1 The 1H NMR spectrum shows the presence of a set of para-substituted phenol (A2B2 system) δ H 7.80 (d, 8.8 Hz, 2H) and 6.85 (d, 8.8 Hz, 2H), and three aromatic ring proton signals δ H 6.50 (s, 2.0 Hz, 1H), 6.44 (d, 8.0 Hz, 1H), and 6.55 (dd, 8.0, 2.0 Hz, 1H), suggesting the presence of an additional asymmetric trisubstituted benzene ring. 13The CNMR spectrum shows 25 well-resolved resonance peaks, including one fully substituted five-membered α,β-unsaturated lactone ring δ C 170.4 (C), 139.6 (C), 130.0 (C), 87.9 (C), one amide carbon signal at 174.0 (C), and one prenyl group with a trisubstituted double bond δ C 28.7 (CH2), 123.6 (CH), 132.9 (C), 25.9 (CH3), 17.8 (CH3), and two methylene signals δ C 42.9 (CH2) and 29.2 (CH2).
[0143] Further analysis Figure 47 of the two-dimensional spectrum (HSQC) (see Table 3) shows that in 1 the H- 1 H-COSY spectrum ( Figure 46 ), H-2'(6') (δ H 7.80, d, 8.8) / H-3'(5') (δ H 6.78, d, 8.8); H-5” (δ H 6.44, d, 8.5) / H-6” (δ H 6.55, dd, 8.5, 2.0); H-7” (δ H 3.09, m) / H-8” (δ H 5.08, t, 6.5). And Figure 48 in the HMBC spectrum, H-4a (δ H 3.38, d, 15.0), H-4b (δ H 3.41, d, 15.0) / C-2 (δ C 170.4, C), C-1” (δ C 125.6, C); H-7” (δ H 3.09, m) / C-2” (δ C 132.5, C), C-3” (δ C 128.4, C), C-4” (δ C 154.9, C), and C-9” (δ C 132.9, C); H-8” (δ H 5.08, t, 6.5) / C-3” (δ C 128.4, C), C-9” (δ C 132.9, C), and C-10” (δ C 25.9, C); H-11” (δ H 1.67, s) / C-9” (δ C132.9, C), and C-10” (δ C 25.9, C) to determine the planar structure of compound F5 (see Figure 39 ).
[0144] Similarly, based on the biogenetic pathway and quantum chemical ECD calculations (Figure 40), the absolute configuration of compound F5 was determined to be 5R.
[0145] Aspergteroid L (compound F6), pale yellow oily gum (MeOH), [α] 25 D +68.5; UV (MeOH) λ max (logε): 224 (3.95), 276 (2.76); IR (neat)νmax : 3334, 1749, 1683, 1259 cm -1 .
[0146] Figure 49 is the HRESIMS spectrum of compound F6; Figure 50 is the IR spectrum of compound F6; Figure 51 is of compound F6 1 1H NMR spectrum (400 MHz, CD3OD); Figure 52 is of compound F6 13 13C NMR spectrum (100 MHz, CD3OD); Figure 53 is the DEPT 135 (100 MHz, CD3OD) spectrum of compound F6; Figure 54 is of compound F6 1 H- 1 H COSY spectrum; Figure 55 is the HSQC spectrum of compound F6; Figure 56 is the HMBC spectrum of compound F6.
[0147] Figure 49 The quasi-molecular ion peak m / z: 408.1449 [M-H] - (calculated value: 408.1447) was given by HRESIMS in 23 to determine its molecular formula as C 23 H Figure 52 in 13 13C NMR and Figure 53 in the DEPT spectrum, compared with F6, F5 lacks an olefinic proton signal δ H 5.08 (t, 6.5) and two olefinic carbon signals δ C123.6 (CH), 132.9 (C), compared with the two methylene groups and one oxygen - connected sp 3 carbon in F5, there are three methylene groups and two oxygen - connected sp 3 quaternary carbons in F6. The data indicates that the dihydropyran ring is fused with the trisubstituted benzene ring, replacing the independent pentenyl chain in F5, and combining 1 H - 1 the key relevant signals of H - COSY, H - 7” (δ H 2.71, t, 6.6) / H - 8” (δ H 2.71, t, 6.6) and the relevant signals in the HMBC spectrum, H - 7” (δ H 2.57, m) / C - 2” (δ C 132.7, CH), C - 3” (δ C 126.0, C), C - 4” (δ C 154.2, C), C - 8” (δ C 33.7, CH2) and C - 9” (δ C 75.1, C); H - 8” (δ H 1.71, t, 6.5) / C - 3” (δ C 126.0, C), C - 7” (δ C 23.2, CH2), C - 9” (δ C 75.1, C) and C - 10” (δ C 27.0, CH3) establish the dihydropyran ring fused through the C3” - C4” bond of the benzene ring.
[0148] According to the biogenetic pathway and quantum chemical ECD calculation (Figure 40), the absolute configuration of compound F6 is determined to be 5R.
[0149] Aspergteroid M (compound F7) is a pale yellow oily gum (MeOH), [α] 25 D +61.2; UV (MeOH) λ max (logε): 226 (4.15), 306 (4.43); IR (neat)νmax : 3338, 1745, 1683, 1516 cm -1 .
[0150] Figure 59 is the HRESIMS spectrum of compound F7; Figure 60 is the IR spectrum of compound F7; Figure 61 is of compound F7 1 1H - NMR spectrum (400 MHz, CD3OD); Figure 62 is of compound F713 13C NMR spectrum (100 MHz, CD3OD); Figure 63 is the DEPT 135 (100 MHz, CD3OD) spectrum of compound F7; Figure 64 is of compound F7 1 H- 1 H COSY spectrum; Figure 65 is the HSQC spectrum of compound F7; Figure 66 is the HMBC spectrum of compound F7.
[0151] Figure 59 The quasi-molecular ion peak m / z: 340.0834 [M-H] given by HRESIMS - (calculated value: 340.0821), determining its molecular formula to be C 18 H 15 NO6, with an unsaturation degree of 12. Comparing the NMR data of compound F7 with that of compound F5, it is found that the two are very similar. The NMR of compound F7 shows that it contains two para-substituted aryl groups: [δ H 6.66 d 8.8 Hz 2H, H-2' / 6', 6.85 d 8.8 Hz 2H, H-3' / 5'; δ C 132.6 (CH), 116.3 (CH), δ H 7.80 d 8.8 Hz 2H, H-2'' / 6'', 6.52 d 8.8 Hz 2H, H-3'' / 5''; δ C 130.9 (CH), 115.5 (CH)], without isopentenyl information δ C 28.7 (CH2), 123.6 (CH), 132.9 (C), 25.9 (CH3), 17.8 (CH3). 1 H- 1 H-COSY spectrum ( Figure 64 ) shows H-2'(6′) (δ H 6.66 d 8.8) / H-3'(4') (δ H 6.85 d 8.8) H-2''(6'') (δ H 6.66, d, 8.8) / H-3''(5'') (δ H 6.52, d, 8.8), combined with the relevant signals in the HMBC spectrum H-6 (δ H 3.41, s) / C-3 (δ C 139.7, C), C-4 (δ C 129.2, C), C-5 (δ C 87.9, C), C-1'' (δ C131.2, C), and C-2” (6”) (δ C 132.6, C), thus determining the planar structure of compound F7 ( Figure 57 and Table 4). According to the biogenetic pathway and quantum chemical ECD calculations ( Figure 58 ). The absolute configuration of compound F7 was determined to be 5R.
[0152] Table 4. 1 1H NMR and 13 13C NMR spectroscopic data (δ in ppm, J in Hz, solvent methanol)
[0153]
[0154]
[0155] Aspergteroid N (compound F8) is a pale yellow oily gum, [α] 25 D +65.8 (c 0.10, MeOH); UV (MeOH) λ max (log ε): 230 (3.40), 306 (4.43) nm; IR (neat)νmax : 3336, 1734, 1519, 1255 cm -1 ;
[0156] Figure 67 is the HRESIMS spectrum of compound F8; Figure 68 is the IR spectrum of compound F8; Figure 69 is of compound F8 1 1H NMR spectrum (400 MHz, CD3OD); Figure 70 is of compound F8 13 13C NMR spectrum (100 MHz, CD3OD); Figure 71 is the DEPT 135 (100 MHz, CD3OD) spectrum of compound F8; Figure 72 is of compound F8 1 H- 1 H COSY spectrum; Figure 73 is the HSQC spectrum of compound F8; Figure 74 is the HMBC spectrum of compound F8.
[0157] Figure 67 The quasimolecular ion peak m / z: 437.1602 [M-H] - (calculated value: 437.1600) given by HRESIMS in 25 determines its molecular formula to be C 27O7, with an unsaturation degree of 13. The NMR data of compound F8 and compound F6 are extremely similar, except that no nitrogen-containing information is observed, while ethyl information is added [δ H 4.25, q, 7.0 Hz, H-8; δ H 1.21, t, 7.0 Hz, H-9; δ C 63.6(CH2)δ C 14.3(CH3)], suggesting that they may have the same skeletal information. At the same time, HMBC re-shows that δ H 4.25(q,7.0) is correlated with δ C 171.1(C-7), determining its planar structure( Figure 57 )
[0158] Similarly, based on the biogenetic pathway and quantum chemical ECD calculation( Figure 58 ). The absolute configuration of compound F8 is determined to be 5R.
[0159] Aspergteroid O (compound F9) is a pale yellow oily gum, [α]25D +83.5(c 0.10,MeOH); UV(MeOH)λ max (logε): 226(4.15), 306(4.33), 320(3.02)nm; IR (neat)νmax : 3307,1739,1498,1257cm -1 ;
[0160] Figure 75 is the HRESIMS spectrum of compound F9; Figure 76 is the IR spectrum of compound F9; Figure 77 is compound F9's 1 1H NMR spectrum (400 MHz, CD3OD); Figure 78 is compound F9's 13 13C NMR spectrum (100 MHz, CD3OD); Figure 79 is the DEPT 135(100 MHz, CD3OD) spectrum of compound F9; Figure 80 is compound F9's 1 H- 1 H COSY spectrum.
[0161] Figure 75 The quasi-molecular ion peak m / z: 407.1493 [M-H] - (calculated value: 407.1495) given by HRESIMS in 24 determines its molecular formula to be C 24O6, with an unsaturation degree of 13. Comprehensive analysis of the 1D NMR spectra of compound F9 and compound F8 shows that their NMR spectra are basically similar, except that one methylene group information is reduced [δ H 4.25, q(7.0) and δ C 63.6 (CH2)]; at the same time, observing HMBC, it is found that δ H 3.49, s, 1H, H-8 is correlated with δ C 171.3 (C-7), and its planar structure is determined ( Figure 57 ).
[0162] Similarly, based on the biogenetic pathway and quantum chemical ECD calculations ( Figure 58 ), the absolute configuration of F9 is determined to be 5R.
[0163] Crystallographic data of compound F1: C 22 H 23 NO4 (M = 365.41 g / mol): Orthorhombic system, space group P212121 (no. 19), Z = 4, T = 173.00(10) K, μ(Cu Kα) = 0.719 mm -1 , Dcalc = 1.290 g / cm 3 , 17318 reflections measured (4.934° ≤ 2Θ ≤ 147.694°), 3749 unique (R int = 0.0508, R sigma = 0.0449). The final R1 was 0.0514 (I > 2σ(I)) and wR2 was 0.1072. Flack parameter 0.02(11). The crystallographic data of compound F1 have been deposited in the Cambridge Crystallographic Data Center (number: CCDC 2262868).
[0164] Crystallographic data of compound F3: C 21 H 27 NO7 (M = 405.43 g / mol): Orthorhombic system, space group P212121 (no. 19), Z = 4, T = 170.1(2) K, μ(Cu Kα) = 0.810 mm -1 , Dcalc = 1.297 g / cm 3 , 14163 reflections measured (6.68° ≤ 2Θ ≤ 147.976°), 4145 unique (R int = 0.0295, R sigma= 0.0239). The final R1 was 0.0766 (I > 2σ(I)) and wR2 was 0.2145. Flack parameter 0.04(8). The crystallographic data of Compound F3 have been deposited at the Cambridge Crystallographic Data Centre (CCDC No.: 2267460).
[0165] Crystallographic data of Compound F4: C 21 H 23 NO5 (M = 369.40 g / mol): Monoclinic, space group P21 (no. 4), β = 97.254(4)°, Z = 2, T = 169.99(10) K, μ(Cu Kα) = 0.694 mm -1 , Dcalc = 1.183 g / cm 3 , 4255 reflections measured (3.998° ≤ 2Θ ≤ 148.31°), 3844 unique (R int = 0.1226, R sigma = 0.0806) The final R1 was 0.1516 (I > 2σ(I)) and wR2 was 0.3945. Flack parameter -0.2(2). The crystallographic data of Compound F4 have been deposited at the Cambridge Crystallographic Data Centre (CCDC No.: 2267462).
[0166] Example 2: Application of γ - arylbutenolide compounds in the preparation of cardiovascular protective drugs
[0167] I. Cell activity evaluation
[0168] The cytotoxicity of Compounds F1 - F13 against H9c2 cardiomyocyte cell line was detected using the Cell Counting Kit - 8 (CCK - 8). The cell viabilities of each drug - administered group and the blank group after incubation at 37°C for 48 hours were compared (p < 0.05). The results showed that Compounds F1 - F13 did not exhibit obvious cytotoxic effects at concentrations of 0, 0.1, 1, 10 μM.
[0169] II. Evaluation of cardiovascular protection
[0170] The protective effects of compounds F1-F13 against tert-butyl hydroperoxide (TBHP)-induced apoptosis in H9c2 cells were evaluated. Cell damage was estimated based on cell viability. The results showed that TBHP significantly reduced cell viability (p<0.05). Among them, compounds F1-F7 and F9-F11 had protective effects at low concentrations, and the protection rates compared with the model group were F1: 14.01%, F2: 0.36%, F8: 1.05%, F9: 0.27%. The protection rates of F6 and F10 were increased by 19.3% and 27.2% respectively compared with the positive drug diazoxide. However, compounds F8, F9, F12 and F13 could not increase cell viability at these three low concentrations (0.1, 1 and 10 μM), suggesting that the cardioprotective effect of γ-butenolide compounds may be related to their phenyl and phenyl disubstitution types and nitrogen element.
[0171] Based on the evaluation results of cardioprotective effects and the similarity of chemical structures, to explore the possible mechanism of cardioprotective effect of F1, the top 100 potential mechanism genes of F1 and F2 were predicted using the Swiss Target Prediction database, and 24 overlapping genes were obtained from the Venn diagram. The protein-protein interaction (PPI) network was established using the STRING 11.5 database and Cytoscape 3.9.0 software, and the key targets and the size and color of the symbols representing degree scores in the network analysis were screened. The results of PPI analysis showed that glycogen synthase kinase-3β (GSK-3β) had the highest degree score, indicating that GSK-3β might be an essential protein for F1.
[0172] We found that after TBHP-induced oxidative stress injury in cardiomyocytes, F1 could inhibit the activity of GSK-3β, down-regulate the activation of NLRP3 inflammasome, and reduce the inflammatory response. The expression changes of Bcl-2 / Bax and caspase 3 indicated that compound F1 could effectively inhibit cell apoptosis and protect cardiomyocytes.
[0173] Compound F1 had a protective effect against apoptosis of H9c2 cells induced by low-concentration TBHP. We further attempted to explore its possible mechanism through network pharmacology and the TBPH-induced oxidative stress injury model of cardiomyocytes. The results showed that compound F1 might reduce the inflammatory response and protect cardiomyocytes through the GSK-3β / NLRP3 pathway. At the same time, regulate the expression of caspase 3 and Bax, up-regulate the anti-apoptotic gene Bcl-2, improve the antioxidant capacity of cells, and inhibit cell apoptosis.
Claims
1. A compound, characterized in that, Its structural formula is as follows:
2. The preparation method of the compound according to claim 1, characterized in that, It is isolated from the fermentation culture of the marine herbal soft coral symbiotic fungus Aspergillus sp. EGF7-0-1, and specifically includes the following steps: 1) Prepare a single medium for the marine herbal soft coral symbiotic fungus Aspergillus sp. EGF7-0-1; 2) Extract the single medium combined with the bacterial cells with ethyl acetate, and then concentrate the extract to obtain the ethyl acetate extract of the rice single culture; 3) The ethyl acetate extract of rice monoculture was separated by silica gel column chromatography, and eluted with petroleum ether / ethyl acetate with V PE :V EtOAc = 100:0 → 0:100 to obtain 11 crude fractions, Fr.1 - Fr.
11. The 5th crude fraction, Fr.5, was separated by silica gel column chromatography and eluted with V CH2Cl2 :V MeOH = 80:1 - 0:100 of CH2Cl2 / MeOH to obtain 6 fractions, namely Fr.5 - 1 - Fr.5 - 6. Fr.5 - 1 was eluted with V CH2Cl2 :V MeOH = 80:1 - 0:100 of CH2Cl2 / MeOH by silica gel column chromatography to obtain 3 fractions, namely Fr.5 - 1 - 1 - Fr.5 - 1 - 3; Fr.5 - 1 - 2 was separated by Sephadex LH - 20 gel column chromatography and eluted with methanol to obtain 5 sub - fractions, namely Fr.5 - 1 - 2 - 1 - Fr.5 - 1 - 2 - 5; The 4th sub - fraction, Fr.5 - 1 - 2 - 4, was purified by SP - HPLC with V MeOH :V H2O = 55:45 as the mobile phase to obtain compound F1 with a retention time of 40.2 min.
3. The preparation method according to claim 2, characterized in that, Step 1) Preparing the single medium for the marine herbal soft coral symbiotic fungus Aspergillus sp. EGF7-0-1 specifically includes the following steps: a. Inoculate the marine herbal soft coral symbiotic fungus Aspergillus sp. EGF7-0-1 into a culture flask containing PDA medium, and culture it on a shaker at 28 °C to obtain an activated seed culture solution; b. Inoculate the activated seed culture solution into a culture flask containing rice medium for single culture, and statically culture it at 28 °C for 30 days.
4. The preparation method according to claim 3, characterized in that, The formula of the rice medium is: 100 g of rice, 115 mL of water, salinity 3.3%, and pH natural.
5. The preparation method according to claim 3, characterized in that, The formula of the PDA medium is: 200 g of potato, 20 g of glucose, 15 - 20 g of agar, 1000 mL of water, salinity 3.5%, and pH natural.
6. Use of the compound according to claim 1 in the preparation of a cardiovascular protection drug.
Citation Information
Patent Citations
A microbial preparation method for selenocyanidin
CN109439705B
Cited By
Chloro-butenelactone compound capable of preventing and treating plant diseases as well as preparation method and application of chloro-butenelactone compound
CN120904137A
